Bioxytran (OTCMKTS:BIXT) Posts Quarterly Earnings Results

Bioxytran (OTCMKTS:BIXT) released its quarterly earnings data on Thursday. The company reported ($0.01) EPS for the quarter, Zacks reports.

Bioxytran Stock Performance

Bioxytran stock traded down $0.02 during trading on Thursday, hitting $0.13. The company’s stock had a trading volume of 245,639 shares, compared to its average volume of 278,622. The stock has a market capitalization of $11.10 million, a price-to-earnings ratio of -12.60 and a beta of 2.00. The stock’s fifty day moving average is $0.11 and its 200 day moving average is $0.10. Bioxytran has a 1-year low of $0.06 and a 1-year high of $0.21.

About Bioxytran

Bioxytran, Inc, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.